Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies

BACKGROUND: Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Singleton, Kyle W, Porter, Alyx B, Hu, Leland S, Johnston, Sandra K, Bond, Kamila M, Rickertsen, Cassandra R, De Leon, Gustavo, Whitmire, Scott A, Clark-Swanson, Kamala R, Mrugala, Maciej M, Swanson, Kristin R
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447137/
https://ncbi.nlm.nih.gov/pubmed/32864609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa085
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados